1 results match your criteria: "Kyoto University Graduate School of Medicine Kyoto 606-8507[Affiliation]"
Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.
Am J Cancer Res
September 2015
Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine Kyoto 606-8507, Japan.
Article Synopsis
- 5-Fluorouracil (5-FU) is a crucial chemotherapy drug for treating esophageal squamous cell carcinoma (ESCC), but resistance to it poses a major challenge.
- Researchers developed a 5-FU-resistant ESCC cell line, TE-5R, which showed significantly higher resistance to 5-FU and had enhanced expression of the DPD enzyme responsible for 5-FU degradation.
- Gimeracil, a DPD inhibitor, was found to increase the effectiveness of 5-FU in TE-5R cells, suggesting that targeting DPD might offer new treatment strategies for overcoming 5-FU resistance in ESCC.